ALGS - Company ID 0001799448
The table below shows Aligos Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.30M | $37.00M | $135.70M | $81.35M | $186.82M | $220.38M |
| Short-term investments | $59.54M | $19.94M | $44.48M | $44.48M | $3.92M | $23.13M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $82.86M |
| $62.14M |
| $141.08M |
| $133.54M |
| $204.42M |
| $250.02M |
| Property, plant & equipment | $1.87M | $2.36M | $3.26M | $4.82M | $6.18M | $8.01M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $88.53M | $70.09M | $151.53M | $146.69M | $235.37M | $265.30M |
| Accounts payable | $3.98M | $2.57M | $2.52M | $4.74M | $3.02M | $3.31M |
| Total current liabilities | $21.23M | $21.74M | $23.91M | $33.13M | $38.96M | $30.27M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $34.99M | $99.07M | $59.45M | $42.79M | $50.64M | $45.26M |
| Retained earnings | -$642.20M | -$618.01M | -$486.80M | -$399.12M | -$303.07M | -$174.74M |
| Total equity | $53.55M | -$28.97M | $92.08M | $103.90M | $184.73M | $220.04M |